Приказ основних података о документу

dc.creatorSantrač, Anja
dc.creatorBijelić, Dunja
dc.creatorStevanović, Vladimir
dc.creatorBanićević, Marija
dc.creatorAranđelović, Jovana
dc.creatorBatinić, Bojan
dc.creatorSharmin, Dishary
dc.creatorCook, James
dc.creatorSavić, Miroslav
dc.date.accessioned2022-03-24T10:08:36Z
dc.date.available2022-03-24T10:08:36Z
dc.date.issued2022
dc.identifier.issn1939-3792
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/4071
dc.description.abstractAutism spectrum disorder (ASD), as a common neurodevelopmental disorder that encompasses impairments in social communication and interaction, as well as repetitive and restrictive behavior, still awaits an effective treatment strategy. The involvement of GABAergic neurotransmission, and especially a deficit of GABA A receptors that contain the α5 subunits, were implicated in pathogenesis of ASD. Therefore, we tested MP-III-022, a positive allosteric modulator (PAM) selective for α5GABAA receptors, in Wistar rats prenatally exposed to valproic acid, as an animal model useful for studying ASD. Postweaning rats of both sexes were treated for 7 days with vehicle or MP-III-022 at two doses pharmacokinetically determined as selective, and thereafter tested in a behavioral battery (social interaction test, elevated plus maze, spontaneous locomotor activ- ity, and standard and reverse Morris water maze). Additional rats were used for establishing a primary neuronal culture and performing calcium imaging, and determination of hippocampal mRNA levels of GABRA5, NKCC1, and KCC2. MP-III-022 prevented impairments in many parameters connected with social, repetitive and restrictive behavioral domains. The lower and higher dose was more effective in males and females, respectively. Intriguingly, MP-III-022 elicited certain changes in control animals similar to those manifested in valproate ani- mals themselves. Behavioral results were mirrored in GABA switch and spontane- ous neuronal activity, assessed with calcium imaging, and also in expression changes of three genes analyzed. Our data support a role of α5GABAA receptors in pathophysiology of ASD, and suggest a potential application of selective PAMs in its treatment, that needs to be researched in a sex-specific manner.
dc.publisherJohn Wiley and Sons Inc
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175076/RS//
dc.relationWe wish to acknowledge the NIH for generous financial support (DA-043204, R01NS076517).
dc.relationThe Milwaukee Institute for Drug Discovery and the University of Wisconsin- Milwaukee’s Shimadzu Laboratory for Advanced
dc.relationApplied Analytical Chemistry for help with spectroscopy and the National Science Foundation, Division of Chemis- try [CHE-1625735]
dc.rightsrestrictedAccess
dc.sourceAutism Research
dc.subjectautism spectrum disorder
dc.subjectKCC2
dc.subjectneuron maturity
dc.subjectNKCC1
dc.subjectvalproic acid animal model
dc.subjectα5GABAA receptor
dc.titlePostweaning positive modulation of α5GABAA receptors improves autism-like features in prenatal valproate rat model in a sex-specific manner
dc.typearticle
dc.rights.licenseARR
dc.citation.rankaM21
dc.identifier.wos000766679200001
dc.identifier.doi10.1002/aur.2699
dc.identifier.scopus2-s2.0-85126062879
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу